Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

Visudyne VIO study recommended to continue

Oct. 18, 2004

Anecortave acetate study results

Oct. 18, 2004

Cand5 enters phase I study for AMD

Oct. 14, 2004

Photrex chosen as new brand name for SnET2

Oct. 11, 2004

Squalamine granted fast track status for wet AMD

Oct. 7, 2004

Therapeutic benefits of omalizumab in allergy conjunctivitis

Oct. 6, 2004

Approvable letter for SnET2 for AMD

Oct. 5, 2004

ISTA and Allergan sign new Vitrase agreement

Oct. 4, 2004

Expanded phase II trial for squalamine opens enrollment

Oct. 1, 2004

ISTA Pharmaceuticals' Vitrase granted three-year market exclusivity

Sep. 23, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...